DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 126 filers reported holding DYNE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $495,966 | +2927.7% | 14,054 | +2335.7% | 0.01% | – |
| Q1 2024 | $16,381 | -81.9% | 577 | -91.5% | 0.00% | -100.0% |
| Q4 2023 | $90,373 | +26.3% | 6,795 | -14.9% | 0.00% | -50.0% |
| Q3 2023 | $71,582 | -24.3% | 7,989 | -4.9% | 0.00% | -33.3% |
| Q2 2023 | $94,534 | +630126.7% | 8,403 | +560.1% | 0.00% | – |
| Q1 2023 | $15 | +66.7% | 1,273 | +73.2% | 0.00% | – |
| Q4 2022 | $9 | -100.0% | 735 | -92.3% | 0.00% | -100.0% |
| Q3 2022 | $122,000 | +838.5% | 9,582 | +425.0% | 0.00% | – |
| Q2 2022 | $13,000 | -94.9% | 1,825 | -93.2% | 0.00% | -100.0% |
| Q1 2022 | $257,000 | +2041.7% | 26,644 | +2442.4% | 0.00% | – |
| Q4 2021 | $12,000 | -47.8% | 1,048 | -28.1% | 0.00% | -100.0% |
| Q3 2021 | $23,000 | -37.8% | 1,458 | -17.4% | 0.00% | 0.0% |
| Q2 2021 | $37,000 | +208.3% | 1,765 | +120.1% | 0.00% | – |
| Q1 2021 | $12,000 | +33.3% | 802 | +78.6% | 0.00% | – |
| Q4 2020 | $9,000 | +350.0% | 449 | +265.0% | 0.00% | – |
| Q3 2020 | $2,000 | – | 123 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
| Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
| GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
| Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
| Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
| COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
| RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |